Best MCL News Podcasts (2024)

1
Inflammation and immune interventions in MDS: targeting STAT, IRAK4, & more 17:29

23h ago17:29

17:29

In myelodysplastic syndromes (MDS), chronic inflammation driven by the innate immune system plays a key role in disease progression. Signal Transducer and Activator of Transcription (STAT) and Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) are critical mediators in this process, where dysregulated signaling leads to aberrant hematopoiesis and t…

1
Updates in the treatment of SCD and thalassemia from EHA 2024: key trial updates, challenges with gene therapies & unmet needs 11:58

8d ago11:58

11:58

Today’s VJHemOnc podcast features experts Rabi Hanna, MD, The Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, Subarna Chakravorty, MBBS, MRCPCH, FRCPath, PhD, King’s College Hospital NHS Foundation Trust, London, UK, and Ali Taher, MD, PhD, FRCP, American University of Beirut Medical Center, Beirut, Lebanon. They discuss key updates in si…

1
Unmet treatment needs in MF: managing prefibrotic disease & thrombocytopenia, novel agents & endpoints for clinical trials 16:00

15d ago16:00

16:00

Myelofibrosis (MF) is a chronic myeloproliferative neoplasm (MPN) characterized by bone marrow fibrosis, extramedullary hematopoiesis, and splenomegaly, often resulting in anemia and thrombocytopenia. There are many unmet treatment needs that remain in this space. This week’s podcast features a discussion from the International Workshop on Myelodys…

1
The role of BTK inhibitors in MCL, ongoing trials & future outlooks: updates from EHA 2024 12:13

22d ago12:13

12:13

The introduction of Bruton's tyrosine kinase (BTK) inhibitors into the treatment landscape for mantle cell lymphoma (MCL) has transformed the field and provided patients with a promising therapeutic option. In this podcast, you will hear from leading experts who discuss the value of these agents in MCL, sharing updates from EHA 2024. Tune in as Man…

1
Novel developments in lower-risk MDS & important practical considerations when treating patients 51:42

29d ago51:42

51:42

In today’s VJHemOnc podcast, we will be sharing novel developments in lower-risk myelodysplastic syndromes (LR-MDS) and important practical considerations when treating patients. You will hear from experts Amer Zeidan, MBBS, Yale University and Yale Cancer Center, New Haven, CT, Rena Buckstein, MD, FRCPC, Odette Cancer Research Program, Sunnybrook …

1
Updates on the use of BCMA-targeting bispecific antibodies in R/R multiple myeloma: insights from EHA & ASCO 2024 16:18

1M ago16:18

16:18

BCMA-targeting bispecific antibodies treat multiple myeloma by binding to BCMA on malignant plasma cells and directing T-cells to initiate targeted cell killing. This podcast provides updates on the use of BCMA-targeting bispecific antibodies in relapsed/refractory (R/R) multiple myeloma from the 2024 American Society of Clinical Oncology (ASCO) Me…

1
Can we trust textile factory audits in China? 25:04

1M ago25:04

25:04

Fresh from his high-profile appearance at a recent US Congressional-Executive Commission on China hearing, Scott Nova, Executive Director of the Workers Rights Consortium in Washington DC, gave Philip Berman a hard-hitting interview questioning the reliability of social compliance audits in China. Scott says about auditing companies working in the …

1
Updates in the treatment of CLL from EHA 2024: BTK and BCL2 inhibitor combinations, BTK degraders, and more 12:10

1M ago12:10

12:10

In today's VJHemOnc podcast, we will be sharing key updates in the treatment of chronic lymphocytic leukemia (CLL) and Richter’s transformation (RT) from the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain. You will hear from experts Toby Eyre, MBChB (Hons), DipMedEd, MRCP (UK), FRCPath (UK), MD, Oxford University Hospit…

1
Highlights from ISA 2024: the importance of early diagnosis in AL amyloidosis, trials in progress & patient selection for SCT 8:43

2M ago8:43

8:43

Welcome to today's VJHemOnc podcast episode, where we will be sharing key highlights from the 2024 International Symposium on Amyloidosis (ISA), which was held in Rochester, MN. This podcast covers a variety of unmet needs in light chain (AL) amyloidosis, as well as emerging trials in the field. Join leading experts Mario Nuvolone, MD, PhD, Univers…

1
Treating LR-MDS beyond ESA failure: currently approved agents, novel approaches & future outlooks 46:31

2M ago46:31

46:31

While there have been advances in the treatment of lower-risk myelodysplastic syndromes (LR-MDS) in recent years, one major challenge that remains is the treatment of patients following the failure of erythropoiesis-stimulating agents (ESAs). In this podcast, experts Amer Zeidan, MBBS, Yale Cancer Center, New Haven, CT, Valeria Santini, MD, Univers…

1
BPDCN treatment and management: CD123-targeting agents, CNS involvement & approaching pediatric/AYA patients 34:39

2M ago34:39

34:39

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive hematologic malignancy originating from plasmacytoid dendritic cells, characterized by skin lesions and frequent involvement of bone marrow and lymphoid tissues. Patients have a poor prognosis, making early diagnosis and advanced treatments, including targeted therapies, crucial …

1
The future of CAR-T therapy in lymphoma, addressing the risk of secondary malignancy & the optimal sequencing of these agents with bispecific antibodies 12:34

3M ago12:34

12:34

Immunotherapeutic approaches, including CAR T-cells and bispecific antibodies, have become well-established in later lines of non-Hodgkin lymphoma (NHL) treatment. CAR T-cells are engineered to target specific antigens expressed on lymphoma cells, and bispecific antibodies simultaneously bind to both tumor cells and immune cells, enhancing the immu…

1
iwMyeloma 2024 Session I: approaching bone disease, clinical trial updates & the value of MRD as an endpoint in trials 27:24

3M ago27:24

27:24

The 17th International Workshop on Multiple Myeloma (iwMyeloma 2024) was held recently in Miami, FL, and brought together experts from around the world to discuss the latest updates, challenges, and research in the field. In this episode, Ola Landgren, MD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, Suzanne Lentzsch, MD, …

1
Managing anemia in MF, key emerging trials in the UK, and approaching young patients with MPNs 11:43

3M ago11:43

11:43

Myelofibrosis (MF) is a hematologic malignancy that causes progressive bone marrow fibrosis and presents with other clinical manifestations, including anemia and splenomegaly. MF-related anemia can be challenging to manage, and strategies are being explored to improve outcomes for patients. Today's VJHemOnc podcast features experts Mary Frances McM…

1
Highlights from EBMT 2024: treating & managing GvHD & understanding the role of the gut microbiome 22:50

4M ago22:50

22:50

Graft-versus-host disease (GvHD) is a common complication following allogeneic stem cell transplantation (alloSCT), which is typically classified as acute or chronic. In this week's VJHemOnc podcast, we'll be sharing key highlights from the 50th Annual Meeting of the EBMT, drawing focus on the biology and treatment of GvHD. Tune in as experts Moham…

1
How to come together to decarbonise with Cascale and 'About You' 30:23

4M ago30:23

30:23

In the final edition of our four-part podcast series, produced in partnership with Cascale, formerly the Sustainable Apparel Coalition, we discuss the need for collective action and pre competitive collaboration to deliver real impact. Regular host Philip Berman is joined by Joyce Tsoi, senior director of the decarbonization program at Cascale, and…

1
The importance of cardio-oncology: awareness around the ESC 2022 guidelines & the value of building MDTs 43:51

4M ago43:51

43:51

In recent years, there has been great emphasis placed on the importance of cardio-oncology, with both cardiologists and hematologists highlighting the value of collaboration between specialists when treating patients with hematological malignancies. Furthermore, the 2022 European Society of Cardiology (ESC) cardio-oncology guidelines aim to help he…

1
Taking the carbon out of clothing, with Cascale 30:52

4M ago30:52

30:52

We sit down with Sean Cady, vice president of global sustainability, responsibility and trade for VF Corporation and also elected board director for Cascale, and Andrew Martin, executive vice president of Cascale for our latest podcast on decarbonising the fashion supply chain. This third of a four part podcast series, features a deep dive into how…

1
Exploring the possibility of early interception in smoldering myeloma: novel agents, challenges & advances in risk stratification 22:22

4M ago22:22

22:22

Smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS) are two well-known precursor conditions to multiple myeloma, and the possibility of early interception is a growing area of interest in the field. In this week's podcast, you will hear from Shaji Kumar, MD, Mayo Clinic, Rochester, MN, Elena Zamagni, MD, …

1
Are you ready for the new EU laws on sustainability? 37:56

4M ago37:56

37:56

In the second of a four part podcast series in partnership with Cascale, formerly known as the Sustainable Apparel Coalition, we look at the potential impact on the textile industry of revolutionary new EU laws on green claims and eco-design. Regular host Philip Berman is joined by Elisabeth von Reitzenstein, senior director of public affairs at Ca…

1
CHIP & CCUS: knowledge gaps, ongoing trials & recommendations for approaching patients with myeloid precursors 13:02

5M ago13:02

13:02

Clonal hematopoiesis of indeterminate potential (CHIP) and clonal cytopenia of unknown significance (CCUS) are considered precursor diseases to hematologic malignancies, indicating early stages of blood disorders that may progress to more serious conditions such as leukemia or myelodysplastic syndromes (MDS). In this podcast, Uma Borate, MD, The Oh…

1
Measuring for impact, with Cascale 34:19

5M ago34:19

34:19

Welcome to a new four part podcast series in partnership with Cascale, formerly known as the Sustainable Apparel Coalition, about the big challenges facing the industry, and Cascale's role in co-creating solutions at scale. The first episode is about Measuring for Impact with host Philip Berman in conversation with: Quentin Thorel, the Group Head o…

1
Monoclonal B-cell lymphocytosis: classification, biology and exploring the possibility of early interception 9:39

5M ago9:39

9:39

Monoclonal B-cell lymphocytosis (MBL) is a condition characterized by the presence of an abnormal increase in B lymphocytes in the blood. MBL is considered a precursor condition to chronic lymphocytic leukemia (CLL); however, not all cases of MBL progress to CLL, and many individuals with MBL do not require treatment. In this podcast, Stephen Ansel…

1
The impact of CAR-T therapy on the myeloma treatment landscape, patient selection for CAR-T & the evolving role of autoSCT 13:00

5M ago13:00

13:00

The introduction of CAR-T therapy has revolutionized the myeloma treatment landscape, offering a promising therapeutic approach for patients with relapsed/refractory (R/R) disease. There are currently two approved CAR-T cells in multiple myeloma: idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), with ongoing studies explor…

1
Diagnosing amyloidosis, currently available therapies & the importance of cardio-oncology 33:31

5M ago33:31

33:31

While there have been advances in the treatment and management of amyloidosis in recent years, diagnosis remains a challenge due to the highly varied presentation of this disease. As clinicians and researchers work to improve outcomes for patients, there is increasing importance being placed on the role of the multidisciplinary team in treating the…

1
Addressing the importance of lymphodepletion, factors contributing to ICAHT & the cost effectiveness of CAR-T therapy 13:02

6M ago13:02

13:02

Although CAR-T cells have revolutionized the treatment of hematological malignancies, there are several important factors that must be addressed regarding the use of these agents. One ongoing challenge is the prevention and management of CAR-T-related toxicities, including immune effector cell-associated hematotoxicity (ICAHT), as well as how to im…

1
Ep 2: Cash for Climate Solutions - figuring out fashion’s CO2 emissions 31:41

6M ago31:41

31:41

In the second episode of this podcast series, produced in partnership with the Apparel Impact Institute about its Climate Solutions Portfolio (CSP), we take a look at the tool it's built to help decide who should get the funding, and what a winning application looks like. As a quick re-cap, the CSP aims to find, feature and fund any initiative, pro…

1
Updates with the use of CAR-T therapy in ALL: ongoing challenges, strategies to overcome resistance & future outlooks 12:58

6M ago12:58

12:58

The treatment landscape of acute lymphoblastic leukemia (ALL) has transformed with the introduction of novel immunotherapeutic agents, including CAR-T cells and antibody-based therapies. Despite these advances, several challenges remain in the field. In today's episode, you will hear the latest updates with the use of CAR-T therapy in ALL, as discu…

1
Ep 1: Cash for climate solutions, with the Apparel Impact Institute 29:37

6M ago29:37

29:37

In partnership with the Apparel Impact Institute, Philip Berman takes an in-depth look at its new The Climate Solutions Portfolio which aims to find, feature and fund any initiative with the potential to reduce energy use and/or greenhouse gas emissions at scale in the industry. And it has up to 250,000 dollars per year to award to projects that ha…

1
TRAIL: How to win cash for climate solutions 1:04

6M ago1:04

1:04

In partnership with the Apparel Impact Institute, host Philip Berman takes an in-depth look at its new The Climate Solutions Portfolio which aims to find, feature and fund any initiative with the potential to reduce energy use and/or greenhouse gas emissions at scale in the industry. And it has up to 250,000 dollars per year to award to projects th…

1
Targeted therapy in AML: the growing role of menin inhibitors & clinical trials exploring these agents 12:10

6M ago12:10

12:10

The treatment landscape of acute myeloid leukemia (AML) has transformed in recent years with the introduction of novel targeted agents, including FLT3 inhibitors, IDH inhibitors, and menin inhibitors. Menin inhibitors are currently being explored in several clinical trials, both as monotherapy and in combination with other agents. In this podcast, …

1
Updates in lower- and higher-risk MDS: challenges, novel agents & key clinical trials at ASH 2023 18:16

6M ago18:16

18:16

Myelodysplastic syndromes (MDS) are a heterogeneous group of hematologic neoplasms which can be categorized into lower- and higher-risk disease (LR-MDS; HR-MDS). Treatment and management strategies vary for LR-MDS versus HR-MDS, and a number of challenges remain in the field. In this podcast, you will hear from leading experts who discuss several t…

1
Key updates in thalassemia at ASH 2023: gene therapies, ongoing trials & the value of precision medicine 12:21

7M ago12:21

12:21

In the last decade, the treatment landscape of thalassemia has been transformed with the introduction of novel therapies. With several agents being evaluated in clinical trials, the future looks promising for patients. Despite these advances, there are challenges and unmet needs which remain, and both clinicians and researchers are working to addre…

1
Updates, challenges and novel agents being explored in BPDCN 9:49

7M ago9:49

9:49

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive and rare hematological malignancy associated with poor prognosis. Several challenges remain in the diagnosis, treatment and management of this disease, with a lack of clinical trials in the field. However, clinicians and researchers are working to improve upon these unmet needs, …

1
Unanswered questions regarding the sequencing of BCMA therapies, the prognostic value of CTCs & the growing role of quadruplets 18:18

7M ago18:18

18:18

The treatment and management of patients with multiple myeloma is continually evolving, giving rise to novel prognostic tools and therapeutic options, with associated benefits and challenges. Several ongoing clinical trials in the field are investigating potential treatment approaches and addressing many unanswered questions. In this podcast, Moham…

1
Key updates in sickle cell disease at ASH 2023: disease biology, ongoing trials & the growing role of gene therapy 11:04

7M ago11:04

11:04

In recent years, the treatment landscape of sickle cell disease (SCD) has been revolutionized with the introduction of novel agents, including recently approved gene therapies. There are several ongoing trials evaluating the safety of these agents in patients, with promising results being demonstrated. In this podcast, leading experts Rabi Hanna, M…

1
ASH 2023 highlights: updates in the diagnosis and treatment of amyloidosis 10:29

7M ago10:29

10:29

In recent years, the treatment and management of light chain (AL) amyloidosis has transformed with the introduction of novel agents. While diagnosis and risk stratification remain a challenge, clinicians and researchers are working to improve upon these. Furthermore, novel immunotherapies are being explored in the field, providing hope for patients…

1
MPN highlights at ASH 2023: novel agents & ongoing clinical trials in ET, PV and MF 17:12

8M ago17:12

17:12

The treatment of the BCR-ABL1-negative myeloproliferative neoplasms (MPNs), including myelofibrosis (MF), polycythemia vera (PV) and essential thrombocythemia (ET), has transformed in recent years. Several clinical trials are exploring the safety and efficacy of novel agents and combinations, with promising advances being made. At the 65th ASH Annu…

1
iwNHL 2023 Session V: Expanding the CAR platform in NHL 10:59

8M ago10:59

10:59

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
iwCLL 2023: The role of continuous BTKis, approaching Richter’s transformation & addressing the underrepresentation of elderly patients in trials 20:50

8M ago20:50

20:50

The biennial International Workshop on Chronic Lymphocytic LeukemiaTM (iwCLL 2023) was held recently in Boston, MA, and brought together experts who shared the latest updates in the treatment and management of CLL. Tune in as we share some key highlights from this year's meeting. In this podcast, a variety of topics are covered, including the role …

1
Threaded Together: How the US Climate Smart Cotton program is helping to reduce the carbon footprint of textiles 46:11

8M ago46:11

46:11

To coincide with the week of World Soil Day 2023, our third and final episode of our Threaded Together: cotton and sustainability podcast series, sponsored by Cotton Incorporated, looks at the US Climate Smart Cotton Program- a bold, new and exciting initiative in the US, which aims to measure and improve the country’s cottons’ carbon footprint. We…

1
iwNHL 2023 Session IV: Novel therapies in NHL: BTK inhibitors, BTK degraders, and bispecific antibodies 15:34

9M ago15:34

15:34

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
Threaded Together: How best to measure cotton’s environmental impact 52:34

9M ago52:34

52:34

In the second of this three-part podcast series: 'Threaded Together' about cotton sustainability, host Philip Berman talks to Dr Jesse Daystar, from Cotton Incorporated and Joel Mertens from the Sustainable Apparel Coalition, about the best way(s) to measure sustainability in the cotton industry and how it can drive change. Jesse and Joel discuss t…

1
Unmet needs in AL amyloidosis, novel treatment strategies being explored, and the role of CHIP 12:23

9M ago12:23

12:23

In recent years, there have been promising therapeutic advances in light chain (AL) amyloidosis, however, several unmet needs remain in this disease. Early and accurate diagnosis present a key challenge, and both clinicians and researchers are investigating novel strategies with the aim of improving outcomes for patients. In this podcast, Angela Di…

1
Has Renewcell been let down by fashion brands? 16:52

9M ago16:52

16:52

Many fashion brands and retailers talk a good game on circularity, but will they ever consistently pay a premium for materials made using 100% textile-to-textile recycling? Acting CEO of Renewcell Magnus Håkansson joins Ecotextile Talks to discuss the company's current challenges in receiving a higher price for a product offering the circularity so…

1
iwNHL 2023 Session III: Recent updates with the use of antibody-drug conjugates in NHL 16:08

9M ago16:08

16:08

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
MPN diagnosis & treatment: novel agents in PV, clinical guidance for the use of JAK inhibitors & the growing role of combination approaches 12:57

9M ago12:57

12:57

The treatment and management of myeloproliferative neoplasms (MPNs) including myelofibrosis (MF) and polycythemia vera (PV) has transformed in recent years, although several challenges remain. There are ongoing clinical trials investigating the safety and efficacy of novel agents for this group of diseases, as well as strategies to improve the diag…

1
iwNHL 2023 Session II: The evolving treatment landscape in mantle cell lymphoma 14:37

10M ago14:37

14:37

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
iwNHL 2023 Session I: Updates on the biology and treatment of T-cell lymphoma 13:52

10M ago13:52

13:52

The 20th International Workshop on Non-Hodgkin Lymphoma (iwNHL 2023) took place in Miami, FL, and brought together leading experts as they discussed the latest clinical updates in the field. In this podcast series, you will hear the latest advances in the treatment and management of lymphoma and gain an insight into the sessions that took place at …

1
Threaded Together: Cotton and Sustainability 46:44

10M ago46:44

46:44

In a new three-part sponsored series entitled, Threaded Together, podcast host Philip Berman looks at Cotton Incorporated's role in improving the sustainability of cotton in the textile industry. Cotton Incorporated a US-based, not-for-profit company, provides resources and research to help companies develop and market innovative, and profitable co…

Podcasts Worth a Listen

MCL News Podcasts

Podcasts Worth a Listen

Quick Reference Guide